Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma

MLA

Christophe Le Tourneau, et al. “Phase I Dose-Escalation Study of F50067, a Humanized Anti-CXCR4 Monoclonal Antibody Alone and in Combination with Lenalidomide and Low-Dose Dexamethasone, in Relapsed or Refractory Multiple Myeloma.” Oncotarget, vol. 9, no. 35, Jan. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ebcc0a77ba30e7973d41884e90ad6a62&authtype=sso&custid=ns315887.

APA

Christophe Le Tourneau, Xavier Leleu, Michel Attal, Cécile Gruchet, Margaret Macro, Paul Franques, Valentine Richez, Thomas Syshenko, Lotfi Benboubker, Florence Sabirou, Helene Gardeney, Pierre Ferré, Lionel Karlin, Mariya Pavlyuk, Anthony Levy, M. Ouali, Jean-Claude Vedovato, Thierry Facon, Arthur Bobin, … Anne-Marie Stoppa. (2018). Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma. Oncotarget, 9(35).

Chicago

Christophe Le Tourneau, Xavier Leleu, Michel Attal, Cécile Gruchet, Margaret Macro, Paul Franques, Valentine Richez, et al. 2018. “Phase I Dose-Escalation Study of F50067, a Humanized Anti-CXCR4 Monoclonal Antibody Alone and in Combination with Lenalidomide and Low-Dose Dexamethasone, in Relapsed or Refractory Multiple Myeloma.” Oncotarget 9 (35). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ebcc0a77ba30e7973d41884e90ad6a62&authtype=sso&custid=ns315887.